Consensus Personalis, Inc.

Stocks

PSNL

US71535D1063

Healthcare Facilities & Services

Market Closed - Nasdaq 16:00:00 2026-10-16 EDT			5-day change	1st Jan Change
15.65 ^USD	-1.76%		-2.19%	+96.61%

10-06	BTIG Downgrades Personalis to Neutral From Buy	MT
08-24	Personalis Shares Fall After Craig-Hallum Downgrade	MT

Evolution of the Average Target: Personalis, Inc.

Evolution of the Target Price: Personalis, Inc.

Changes in Analyst Recommendations: Personalis, Inc.

b.4DsIeD9NXf8j953O6jH6LfHoEBRPt0_K1lKnuHV8Fgo.i3JMNUsuO7Jtp66Z3nqTR4XdZHsg0iKz4z2e7D87ckGvU3oWWngUtxCT9g~39da1ffa0cab724bc5085531411e8dde

Analysts' recommendations: Personalis, Inc.

10-06	BTIG Downgrades Personalis to Neutral From Buy	MT
08-24	Personalis Shares Fall After Craig-Hallum Downgrade	MT
08-24	Craig-Hallum Downgrades Personalis to Hold From Buy, Price Target is $16.25	MT
07-20	Personalis Acquisition Price Warranted by Growth Prospects, Needham Says	MT
07-20	Top Midday Decliners	MT
07-20	Needham Downgrades Personalis to Hold From Buy	MT
07-17	Needham Raises Price Target on Personalis to $17 From $12, Keeps Buy Rating	MT
05-12	Morgan Stanley Cuts Price Target on Personalis to $9 From $10, Keeps Equalweight Rating	MT
12-02	Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating	MT
25-08-05	Healthcare firm Personalis' Q2 revenue misses estimates	RE
25-05-15	Guggenheim Initiates Personalis at Buy With $6 Price Target	MT
25-03-17	Craig Hallum Initiates Coverage on Personalis With Buy Rating, $8 Price Target	MT
24-08-16	BTIG Raises Personalis' Price Target to $7 From $5.50, Buy Rating Maintained	MT
24-08-08	Needham Adjusts Personalis' PT to $5.50 From $3.50, Keeps Buy Rating	MT
24-04-30	Lake Street Starts Personalis With Buy Rating, $4 Price Target	MT
24-02-29	Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating	MT
23-11-08	Needham Cuts Price Target on Personalis to $2.30 From $7, Maintains Buy Rating	MT
23-08-09	HC Wainwright Adjusts Price Target on Personalis to $7.50 From $10, Maintains Buy Rating	MT
23-05-04	Needham Trims Price Target on Personalis to $7 From $8, Maintains Buy Rating	MT
23-02-27	Morgan Stanley Adjusts Price Target on Personalis to $5 From $11, Maintains Equal-Weight Rating	MT
23-02-24	HC Wainwright Trims Price Target on Personalis to $10 From $13, Maintains Buy Rating	MT
23-02-06	Needham Upgrades Personalis to Buy From Hold, Says Encouraged by Cost Reductions, Price Target is $8	MT
22-11-03	HC Wainwright Adjusts Personalis' Price Target to $13 From $26, Keeps Buy Rating	MT
22-11-03	Citigroup Adjusts Price Target on Personalis to $6 From $8, Maintains Buy Rating	MT
22-08-04	Citigroup Lowers Personalis' Price Target to $8 From $14, Maintains Buy Rating	MT

More recommendations

Medical & Diagnostic Laboratories

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PERSONALIS, INC.					-3.09%
	CVS HEALTH CORPORATION					+25.03%
	HCA HEALTHCARE, INC.					+0.38%
	NATERA, INC.					+2.66%
	QUEST DIAGNOSTICS INCORPORATED					+6.98%
	LABCORP HOLDINGS INC.					+8.55%
	TENET HEALTHCARE CORPORATION					+7.17%
	DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY					+19.97%
	REDE D'OR SÃO LUIZ S.A.					+15.39%
	IHH HEALTHCARE					+27.91%
	Average					+11.09%
	Weighted average by Cap.					+12.02%